- Published at
- by manilatimes.net
positive
positive
News for Annovis Bio, Inc. (ANVS)
- Published at
- by gurufocus.com
positivepositiveAnnovis to Attend AD/PD™ 2025 with Extensive Scientific Program
MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative- Published at
- by gurufocus.com
neutralneutralAnnovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the ”Company”), a late-stage clinical drug platform company p- Published at
- by manilatimes.net
neutralneutral- Published at
- by gurufocus.com
positivepositiveAnnovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment
MALVERN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative- Published at
- by financialpost.com
neutralneutralAnnovis to Host Patients' Live Forum on February 27, 2025
MALVERN, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company deve…- Published at
- by manilatimes.net
neutralneutral- Published at
- by financialpost.com
neutralneutralAnnovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company p…- Published at
- by manilatimes.net
neutralneutral- Published at
- by rttnews.com
positivepositiveAnnovis Bio Prices Offering Of 5.25 Mln Shares At $4/Share, Stock Falls In Pre-Market
Late-stage clinical drug platform company Annovis Bio, Inc. (ANVS), Monday announced the pricing of 5.25 million common stock and warrants to purchase an equal number of shares at a combined price of $4 per share, amounting to a total of $21 million.- Published at
- by manilatimes.net
mixedmixed- Published at
- by manilatimes.net
mixedmixed- Published at
- by financialpost.com
neutralneutralAnnovis Bio, Inc. Announces Proposed Public Offering
MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company …- Published at
- by gurufocus.com
positivepositiveAnnovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace
LOS ANGELES, Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- InvestorBrandNetwork, a multifaceted communications organization engaged in connecting public compan- Published at
- by manilatimes.net
positivepositive- Published at
- by investing.com
positivepositiveAnnovis to Host Year-End Investor Webcast on December 11, 2024 By Investing.com
Annovis to Host Year-End Investor Webcast on December 11, 2024- Published at
- by globenewswire.com
positivepositiveAnnovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) (- Published at
- by seekingalpha.com
negativenegativeAnnovis Bio: Funding May Be An Issue For Announced Phase 3 Trials (NYSE:ANVS)
Annovis faces financial challenges and questionable efficacy in Alzheimer's and Parkinson's trials, risking poor stock performance. Learn more on ANVS stock here.- Published at
- by gurufocus.com
positivepositiveAnnovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug
Oct. 17, 2024 ”“ The market is enthusiastic to Annovis Bio, Inc. (ANVS) and some say that they tackle Alzheimer's and Parkinson's in ways humanity has never ac- Published at
- by globenewswire.com
positivepositiveFDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform...